AIIMS panel gives nod to human clinical trial of anti-coronavirus drug Covaxin
4 years, 5 months ago

AIIMS panel gives nod to human clinical trial of anti-coronavirus drug Covaxin

India Today  

The AIIMS Ethics Committee on Saturday gave its nod for a human clinical trial of the indigenously developed Covid-19 vaccine candidate Covaxin following which the premier hospital is likely to begin the exercise by enrolling healthy volunteers from Monday. "The AIIMS Ethics Committee gave its approval for starting the human clinical trial of the indigenously developed Covaxin today. Covid-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology, had recently got the nod for human clinical trials from the Drugs Controller General of India. Noting that this was the first indigenous vaccine being developed by India, ICMR Director General Dr Balram Bhargava in a letter to principal investigators of the 12 sites recently had asked them to fast-track the human clinical trial approvals stating it is one of the "top priority projects which is being monitored at the top-most level of the government".

India Trial Human Rai Vaccine Developed Dcgi Clinical Icmr Aiims Covaxin Human Clinical Trial  nod  icmr  trials  gives  human  drug  clinical  vaccine  phase  covaxin  volunteers  panel  aiims  developed  trial  anticoronavirus

History of this topic

Welcome development: The Hindu Editorial on the ICMR and Controlled Human Infection Studies
1 year, 4 months ago

Welcome development: The Hindu Editorial on the ICMR and Controlled Human Infection Studies

The Hindu  

With the Bioethics Unit of the Indian Council of Medical Research placing a consensus policy statement on Controlled Human Infection Studies for comments, India has taken the first step in clearing the deck for such studies to be undertaken here. CHIS, also called human challenge studies, where healthy volunteers are intentionally exposed to a disease-causing microbe in a highly controlled …

Bharat Biotech misstated Covaxin trial data
2 years ago

Bharat Biotech misstated Covaxin trial data

Deccan Chronicle  

HYDERABAD: Extremely serious procedural leniencies and incorrect reporting of the results of trials of Covaxin, Bharat Biotech’s anti-Covid vaccine, have come to light, raising some very uncomfortable questions on the vaccine’s rollout for general use in India. Inquiries and investigation into the three phases of human trials of Covaxin have found grave reporting errors – some that appear to be …

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha
2 years, 8 months ago

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha

News 18  

An ICMR study to examine the effect of Covaxin's booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday. International data available on booster doses of AstraZeneca and Covishield suggests a three- to four-fold increase in antibody levels after their administration, Pawar said …

Holds promise: ICMR on trial results of third dose of Covaxin
2 years, 11 months ago

Holds promise: ICMR on trial results of third dose of Covaxin

Hindustan Times  

A day after Bharat Biotech released the trial results of the safety and immunogenicity of its Covid-19 vaccine ‘Covaxin’ as a booster shot, the Indian Council of Medical Research on Sunday affirmed the findings. Prime Minister Narendra Modi, in a televised address on December 25, 2021, announced precaution doses for healthcare and frontline workers from January 10 and Covid-19 jabs …

Bharat Biotech Seeks DCGI Nod for Trials to Evaluate Efficacy of Covaxin Booster Shot - News18
2 years, 11 months ago

Bharat Biotech Seeks DCGI Nod for Trials to Evaluate Efficacy of Covaxin Booster Shot - News18

News 18  

Bharat Biotech has sought permission from India’s drug regulator to conduct clinical trials for evaluating the efficacy of a third dose of its Covid-19 vaccine, Covaxin. According to a top government official, the indigenous vaccine maker has proposed to conduct clinical trials for Covaxin’s booster shot on 5,000 healthy volunteers, keeping a gap of six months between the second and …

How Macaulay Putras Ridiculed Covaxin and Data Proved Them Wrong
3 years, 1 month ago

How Macaulay Putras Ridiculed Covaxin and Data Proved Them Wrong

News 18  

The Phase III human clinical trials of Covaxin began in mid-November 2020, involving 26,000 volunteers, between 18 and 98 years of age, across 21 sites. It was India’s first and only Phase III study for a COVID-19 vaccine, and the largest Phase III efficacy trial ever conducted here for any vaccine. He said that if the East India Company had …

Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy against COVID, says Lancet
3 years, 1 month ago

Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy against COVID, says Lancet

India TV News  

Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech's Covaxin. "COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent," the official statement issued by Bharat Biotech said citing the study by the Lancet. "Efficacy analysis demonstrates Covaxin …

Covaxin gets WHO’s emergency use nod
3 years, 1 month ago

Covaxin gets WHO’s emergency use nod

The Hindu  

India’s first indigenous COVID-19 vaccine, Bharat Biotech’s Covaxin, was granted Emergency Use Listing by the World Health Organization on Wednesday. Union Health Minister Mansukh Mandaviya, welcoming the announcement, said, “This is a proud moment for the entire country.” The WHO in its tweets on Wednesday said that the Technical Advisory Group, convened by the WHO and made up of regulatory …

Covaxin Granted EUL by WHO: Tracing The COVID-19 Vaccine's Journey
3 years, 1 month ago

Covaxin Granted EUL by WHO: Tracing The COVID-19 Vaccine's Journey

The Quint  

On 7 December Bharat Biotech officially applied for Emergency Use Authorisation for Covaxin. On 9 December, However, the DGCI asked Bharat biotech to submit more data for Covaxin before it could be granted an EUA. On 2 January 2021, Covaxin received EUA from the DGCI for restricted use "in public interest as an abundant precaution, in clinical trial mode, specially …

No Nod for Covaxin Yet as WHO Seeks More Data, Final Assessment Likely on November 3
3 years, 1 month ago

No Nod for Covaxin Yet as WHO Seeks More Data, Final Assessment Likely on November 3

News 18  

The World Health Organization on Tuesday once again postponed granting approval to India’s indigenous Covid-19 vaccine Covaxin, seeking more technical details to conduct a final ‘risk-benefit assessment’. The global body — which was reviewing data on India’s Covaxin shot against Covid-19 to grant Emergency Use Listing — has sought additional information from Hyderabad-based Bharat Biotech to conduct a final “risk-benefit …

WHO Reviewing Data on Bharat Biotech’s Covaxin, Decision on Approval in '24 Hours or So'
3 years, 1 month ago

WHO Reviewing Data on Bharat Biotech’s Covaxin, Decision on Approval in '24 Hours or So'

News 18  

The World Health Organization was reviewing data on Covaxin, India’s indigenously-made vaccine against Covid-19 and will announce a decision on its Emergency Use Listing in “24 hours or so” a spokesperson said. WHO Chief Scientist Soumya Swaminathan had said in a tweet earlier that the technical advisory group at the organisation will meet on October 26 to consider the much-coveted …

‘Aware People Are Waiting, But…': WHO Explains Delay in Nod to Covaxin for Emergency Use
3 years, 2 months ago

‘Aware People Are Waiting, But…': WHO Explains Delay in Nod to Covaxin for Emergency Use

News 18  

The World Health Organization on Monday said it is “expecting one additional piece of information” from Bharat Biotech before it thoroughly evaluates COVAXIN for it to be included in the COVID-19 Emergency Use Listing. Covaxin manufacturer, Bharat Biotech, has been submitting data to WHO on a rolling basis and experts have been reviewing them, it said in a series of …

Biological E seeks DCGI’s nod for phase-3 trial of Corbevax as booster dose in those vaccinated with Covishield or Covax
3 years, 2 months ago

Biological E seeks DCGI’s nod for phase-3 trial of Corbevax as booster dose in those vaccinated with Covishield or Covax

Live Mint  

Hyderabad-based pharmaceutical company Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its COVID-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin. The company, meanwhile, has put in an application seeking the nod of the Drugs Controller General of India to conduct the …

Bharat Biotech Submits Clinical Trial Data of Covaxin in Children to CDSC
3 years, 2 months ago

Bharat Biotech Submits Clinical Trial Data of Covaxin in Children to CDSC

News 18  

Bharat Biotech, which completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday. ?Covaxin clinical trial data of 2-18 years age group has …

WHO decision on Bharat Biotech's Covaxin emergency use listing likely next week
3 years, 2 months ago

WHO decision on Bharat Biotech's Covaxin emergency use listing likely next week

Firstpost  

The Strategic Advisory Group of Experts on Immunization of the WHO met on Tuesday to make its recommendations on Covaxin on EUL, among other issues New Delhi: The WHO will take a call on granting Emergency Use Listing status for Bharat Biotech’s COVID-19 vaccine Covaxin next week, the global health body said on Tuesday. “WHO and an independent group of …

WHO to take final call on approval for Bharat Biotech's Covaxin next week
3 years, 2 months ago

WHO to take final call on approval for Bharat Biotech's Covaxin next week

India Today  

The World Health Organisation will take a final call on the emergency use listing for Bharat Biotech's Covaxin by next week. Assessment will be finalized next week: WHO Confirming the same in a series of tweets, the WHO said, "WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come …

The pandemic's silent saviours
3 years, 2 months ago

The pandemic's silent saviours

Deccan Chronicle  

The pandemic shone light on the dedicated contributions of the frontline healthcare workers — doctors, nurses and paramedics. Most scientists associated with COVID-19 research in India have been working in the Indian Council of Medical Research laboratories, such as National Institute of Virology, Pune, Centre For Cellular And Molecular Biology, Hyderabad, and in vaccine manufacturing facilities like Serum Institute of …

AIIMS Director Dr Randeep Guleria hopes for early approval of COVID vaccine Covaxin by WHO
3 years, 2 months ago

AIIMS Director Dr Randeep Guleria hopes for early approval of COVID vaccine Covaxin by WHO

India TV News  

With the data and studies regarding COVID-19 vaccine Covaxin submitted to the World Health Organization, the All India Institute of Medical Sciences Delhi Director Randeep Guleria is hopeful that the authorisation for emergency use listing to the vaccine will be accorded soon. Though individual European countries have recognised the Serum Institute of India's Covishield, however till date the European Union …

Working with WHO for Covaxin approval, Bharat Biotech says after reports of delay
3 years, 2 months ago

Working with WHO for Covaxin approval, Bharat Biotech says after reports of delay

India Today  

Hyderabad-based Bharat Biotech on Tuesday said it is working with the World Health Organisation for approval of emergency use authorisation for Covaxin, the Covid vaccine developed in India, at the earliest. "We request media organisations to exercise restraint while reporting on public health-related issues and timelines, as it has an impact on millions of lives and livelihoods," Bharat Biotech said …

WHO Nod for Covaxin May Take ‘Few More Weeks’ Over Technical Queries; Routine, Says Health Body
3 years, 2 months ago

WHO Nod for Covaxin May Take ‘Few More Weeks’ Over Technical Queries; Routine, Says Health Body

News 18  

The much-awaited approval from the World Health Organisation for India’s home-grown coronavirus vaccine manufactured by Hyderabad-based Bharat Biotech, Covaxin, is likely to be delayed by a few more weeks. Although a set of technical queries have been sent by the international health watchdog, a source in the WHO said that it’s a routine process and there’s no concern in the …

Bharat Biotech completes phase 2/3 trials of Covaxin in children, to submit data by next week
3 years, 3 months ago

Bharat Biotech completes phase 2/3 trials of Covaxin in children, to submit data by next week

Hindustan Times  

Bharat Biotech, the Hyderabad-based biotechnology company and the makers of Covaxin Covid-19 vaccine, on Tuesday said that the phase 2/3 trials of Covaxin for inoculation in children under the age of 18 are over. Briefing on the production of Covaxin, Krishna Ella said that it would reach 55 million doses in October. Bharat Biotech’s chairman and managing director Krishna Ella …

Working to obtain WHO approval for Covaxin at the earliest: Bharat Biotech
3 years, 3 months ago

Working to obtain WHO approval for Covaxin at the earliest: Bharat Biotech

India Today  

Homegrown vaccine developer Bharat Biotech said on Friday that it is continuously working towards securing the World Health Organization’s emergency use nod for its Covid-19 shot, Covaxin. Detailing the timeline of the WHO approval process, Bharat Biotech said in a statement, “Covaxin clinical trial data was fully compiled and available in June 2021. All data was submitted for Emergency Use …

WHO likely to take decision on Covaxin's EUA after October 5
3 years, 3 months ago

WHO likely to take decision on Covaxin's EUA after October 5

India Today  

The Strategic Advisory Group of Experts on Immunization will meet at the World Health Organisation on October 5 to discuss granting the emergency use authorisation to Covaxin. Any decision on the emergency use listing of the Bharat Biotech-made Covid-19 vaccine will be taken only after the meeting on October 5. During the October 5 meeting, the SAGE will also look …

DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life Sciences
3 years, 3 months ago

DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life Sciences

The Hindu  

The Drugs Controller General of India on September 3 granted permission to the Mukesh Ambani-owned Reliance Life Sciences to conduct phase-I clinical trial of its indigenous COVID-19 vaccine with certain conditions, sources said. The phase-I clinical trial will be conducted to evaluate safety, tolerability and immunogenicity of the SARS-CoV-2 recombinant protein subunit vaccine in healthy volunteers according to protocol, they …

DGCI Gives Nod for Phase 2/3 Trials of Biological E's Covid Vaccine for Children
3 years, 3 months ago

DGCI Gives Nod for Phase 2/3 Trials of Biological E's Covid Vaccine for Children

News 18  

The Drugs Controller General of India on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct phase 2/3 clinical trials of its ‘Made in India’ COVID-19 vaccine on children aged between 5 and 18 years with certain conditions, sources said. Meanwhile, the data of phase 2/3 clinical trials of Bharat Biotech’s Covaxin in the age group 2 to 18 …

Maharashtra Company Starts Human Trials of Drug for Mild, Moderate Cases of Covid-19
3 years, 4 months ago

Maharashtra Company Starts Human Trials of Drug for Mild, Moderate Cases of Covid-19

News 18  

A company in western Maharashtra has started human trials of a drug targeted at mild and moderately infected coronavirus patients, a top official said. World's largest vaccine maker Serum Institute of India is the sponsor of the Pune-headquartered iSERA Biological Pvt Ltd's drug project, which began soon after COVID-19 hit Indian shores. The company's primary activity is the manufacturing of …

Covaxin production to get boost as govt approves manufacturing facility in Gujarat's Ankleshwar
3 years, 4 months ago

Covaxin production to get boost as govt approves manufacturing facility in Gujarat's Ankleshwar

India TV News  

Union Health Minister Mansukh Mandaviya on Tuesday informed that the government has approved a vaccine manufacturing facility for the production of Bharat Biotech's Covaxin in Gujarat's Ankleshwar. From January 16 to August 5, 44.42 crore doses of Covishield were supplied by Serum Institute of India and 6.82 crore doses of Covaxin by Bharat Biotech for the National COVID-19 Vaccination Programme. …

Covaxin receives Good Manufacturing Practice certificate from Hungary
3 years, 4 months ago

Covaxin receives Good Manufacturing Practice certificate from Hungary

India Today  

Bharat Biotech's Covaxin has received a certificate of Good Manufacturing Practice from the National Institute of Pharmacy and Nutrition Hungary. The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorisations and certificates of the good manufacturing practice. Read: EU holding back approval for Indian-made AstraZeneca vaccine 'discriminatory', say …

Initial hiccups in Bharat Biotech Bengaluru plant delayed Covaxin production: NTAGI Chief
3 years, 4 months ago

Initial hiccups in Bharat Biotech Bengaluru plant delayed Covaxin production: NTAGI Chief

Live Mint  

New Delhi: India achieved the target of 47 crore COVID-19 vaccine doses till the month of July, Dr N K Arora, Chief of National Immunization Technical Advisory Group said and added that some hiccups like initial difficulties in the new Bangalore plant of Bharat Biotech had delayed the production of Covaxin. Dr NK Arora also said that Bharat Biotech will …

Government funding work on four new COVID-19 vaccine candidates
3 years, 5 months ago

Government funding work on four new COVID-19 vaccine candidates

The Hindu  

The Centre is funding the development of four vaccines, which are currently in various stages of human trials. The government has also funded clinical trial sites, animal challenge facilities and immunoassay laboratories, all of which were collectively allotted a budget of ₹900 crore for 12 months, the Minister said. The four vaccines, being funded under Mission Covid Suraksha, were the …

All documents submitted to WHO for emergency use listing of Covaxin, says Bharat Biotech
3 years, 5 months ago

All documents submitted to WHO for emergency use listing of Covaxin, says Bharat Biotech

Live Mint  

All documents required for Emergency Use Listing of Covaxin have been submitted to the World Health Organisation as of 9 July, Hyderabad-based Bharat Biotech said today. Recently, WHO chief scientist Soumya Swaminathan said that the global health body is likely to take a call on whether to include Bharat Biotech's Covid-19 vaccine Covaxin in the EUL in the next four …

All documents required for emergency use listing of Covaxin submitted to WHO: Bharat Biotech
3 years, 5 months ago

All documents required for emergency use listing of Covaxin submitted to WHO: Bharat Biotech

India Today  

Bharat Biotech on Monday said that all documents required for Emergency Use Listing of Covaxin have been submitted to the World Health Organisation. WHO chief scientist Soumya Swaminathan had on Saturday said that the global health body is likely to take a decision on EUL of Bharat Biotech’s Covid-19 vaccine Covaxin within four to six weeks. Speaking at a webinar …

WHO to take decision on emergency use listing of Bharat Biotech's Covaxin in 4-6 weeks
3 years, 5 months ago

WHO to take decision on emergency use listing of Bharat Biotech's Covaxin in 4-6 weeks

India Today  

World Health Organisation chief scientist Soumya Swaminathan has said that the WHO is likely to take a decision on Emergency Use Listing of Bharat Biotech’s Covid-19 vaccine Covaxin within four to six weeks. Bharat Biotech has now started uploading their data on our portal and that is the next vaccine that will be reviewed by our experts committee,” the chief …

Covaxin approval soon? WHO chief scientist says Phase-3 trial data looks good
3 years, 5 months ago

Covaxin approval soon? WHO chief scientist says Phase-3 trial data looks good

India Today  

As Hyderabad-based pharma firm Bharat Biotech awaits the World Health Organisation's approval for the emergency use listing for Covaxin, WHO Chief Scientist Soumya Swaminathan has said Covaxin's Phase-3 data looks promising and the vaccine can hopefully be approved by the WHO by mid to late August. In a recent interview, Swaminathan said the Phase-3 trial data of Covaxin looks encouraging …

Sanofi, GSK get nod for phase 3 trial of covid-19 vaccine in India
3 years, 5 months ago

Sanofi, GSK get nod for phase 3 trial of covid-19 vaccine in India

Live Mint  

French pharmaceutical Sanofi and its British partner GlaxoSmithKline on Thursday said they have received the approval of the drugs controller general of India to conduct part of the global phase-3 efficacy trial of their jointly developed covid-19 vaccine in India. We believe our covid-19 adjuvanted, recombinant vaccine can make a significant contribution to the ongoing fight against covid-19 and are …

Final analysis of Covaxin efficacy out; 65.2 per cent effective against Delta
3 years, 5 months ago

Final analysis of Covaxin efficacy out; 65.2 per cent effective against Delta

Deccan Chronicle  

Hyderabad: Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant. The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases while safety analysis shows adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side …

Covaxin is 65.2% effective against Delta variant, says Bharat Biotech
3 years, 5 months ago

Covaxin is 65.2% effective against Delta variant, says Bharat Biotech

Op India  

On Saturday, Bharat Biotech announced the safety and efficacy analysis data from Phase-3 clinical trials of Covaxin – an indigenous vaccine developed to fight the deadly pandemic Covid-19. Citing pre-print data from the country’s largest efficacy trial, Bharat Biotech revealed that the Indian-made Covaxin achieved an overall efficacy of 77.8% against symptomatic Covid-19 patients. Here are the overall efficacy rates …

Bharat Biotech's Covaxin shows 77.8% efficacy in Phase 3 trial
3 years, 5 months ago

Bharat Biotech's Covaxin shows 77.8% efficacy in Phase 3 trial

India Today  

Bharat Biotech concluded the final analysis of its Covid-19 vaccine Covaxin and announced the safety and efficacy analysis data from Phase 3 clinical trials on Saturday. The indigenously developed vaccine demonstrated 93.4 per cent efficacy against severe symptomatic Covid-19 and 63.6 per cent efficacy against SARS-CoV-2 B.1.617.2, known as the Delta variant. Covaxin demonstrated 63.6 per cent efficacy against the …

India’s Covaxin effectively neutralises Delta variant of Covid, says U.S.' health research institute
3 years, 5 months ago

India’s Covaxin effectively neutralises Delta variant of Covid, says U.S.' health research institute

The Hindu  

India’s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the U.S.’ National Institute of Health has said. The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 and …

Covaxin effectively neutralises both Alpha, Delta variants of Covid-19: US' top health institute
3 years, 5 months ago

Covaxin effectively neutralises both Alpha, Delta variants of Covid-19: US' top health institute

India TV News  

India's Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US' National Institute of Health has said. The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 and …

Covaxin shows 77.8% efficacy in phase 3 trial, likely to get clearance today
3 years, 6 months ago

Covaxin shows 77.8% efficacy in phase 3 trial, likely to get clearance today

India TV News  

The phase three trial of Bharat Biotech's Covaxin has shown an efficacy of 77.8 per cent in protection against COVID-19, sources said on Tuesday. Meanwhile, in a major boost for Bharat Biotech, the World Health Organisation has accepted its Expression of Interest for Covid-19 vaccine Covaxin and scheduled a pre-submission meeting on June 23, a step that will take the …

Bharat Biotech submits Covaxin's Phase III trial data to DCGI: Govt sources
3 years, 6 months ago

Bharat Biotech submits Covaxin's Phase III trial data to DCGI: Govt sources

India TV News  

The Hyderabad-based COVID vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to Drugs Controller General of India over the weekend, according to government sources. "We have received the data from the phase III trials," a senior government official confirmed. The phase III data of its vaccine have been questioned various times and that …

Covaxin shows 77% efficacy in Phase 3 trials, Bharat Biotech informs govt panel, data under review
3 years, 6 months ago

Covaxin shows 77% efficacy in Phase 3 trials, Bharat Biotech informs govt panel, data under review

India Today  

The results of Phase 3 clinical trials of Bharat Biotech’s Covaxin vaccine have come. Bharat Biotech on Tuesday made a presentation in which the data was presented to the panel, showing 77.8% efficacy of Covaxin. Meanwhile, the World Health Organisation has also accepted Bharat Biotech’s Expression of Interest for Covaxin and has scheduled a pre-submission meeting tomorrow. Bharat Biotech had …

Visakhapatnam COVID Clinical Research Center set for vaccine trials from July
3 years, 6 months ago

Visakhapatnam COVID Clinical Research Center set for vaccine trials from July

Deccan Chronicle  

Visakhapatnam: The Visakhapatnam Covid Clinical Research Center will be ready to facilitate clinical trials by licensed pharma companies from July. We have almost got the center ready and are expecting clinical trials by vaccine manufacturing companies from July. The AMC handled clinical trials for Covishield vaccine in the first wave.” Dr Sudhakar further said that the biotechnology department would take …

Bharat Biotech and WHO to have pre-submission meeting on 23 June to gain Emergency Use Listing
3 years, 6 months ago

Bharat Biotech and WHO to have pre-submission meeting on 23 June to gain Emergency Use Listing

Firstpost  

The External Affairs Ministry is coordinating with Bharat Biotech to secure WHO recognition for COVAXIN. Hyderabad-based Bharat Biotech’s pre-submission meeting has been scheduled on June 23 for evaluation of the World Health Organisation ’s Emergency Use Listing of its indigenous COVID-19 vaccine Covaxin. The External Affairs Ministry is coordinating with Bharat Biotech to secure WHO recognition for the COVID-19 vaccine. …

Serum Institute to Start Trials of Covovax Vaccine on Children in July: Report
3 years, 6 months ago

Serum Institute to Start Trials of Covovax Vaccine on Children in July: Report

News 18  

The Serum Institute of India is planning to start the trials of Novavax’s Covid-19 vaccine in the country on children next month, it was reported on Thursday. It is going to be simple and cheaper with a 90 per cent vaccine effectiveness,” Dr NK Arora, chairperson of the Centre’s Covid Working Group, was quoted as saying by NDTV. In May, …

AIIMS Delhi to resume routine inpatient admissions, elective surgeries
3 years, 6 months ago

AIIMS Delhi to resume routine inpatient admissions, elective surgeries

India TV News  

The AIIMS in New Delhi has decided to resume routine inpatient admissions and elective surgeries at its general and private wards and in all its centres with immediate effect, according to an order by the hospital administration. Delhi was hit badly by a brutal second wave of the COVID-19 pandemic, claiming a massive number of lives daily, with the recent …

Serum Institute To Start Clinical Trials Of Novavax Shot For Children In July
3 years, 6 months ago

Serum Institute To Start Clinical Trials Of Novavax Shot For Children In July

ABP News  

Pune: Pune-based vaccine manufacturer Serum Institute of India plans to start clinical trials of the Novavax shot for children against Covid-19 in July. News agency ANI quoted its sources saying, "Serum Institute of India plans to start clinical trials of the Novavax shot for children in July." Developed by the Maryland-based biotechnology company Novavax, vaccine candidate called NVX-CoV2373 is a …

AIIMS Delhi to start Covaxin trial for children aged 6-12 from today
3 years, 6 months ago

AIIMS Delhi to start Covaxin trial for children aged 6-12 from today

India TV News  

The recruitment for the clinical trial Bharat Biotech's vaccine Covaxin, among children in the age group of 6-12 years will begin at the AIIMS today. Ahead of this, the enrolment of children volunteers aged 12-18 years at the All India Institute of Medical Sciences was completed and they were given the first dose of Covaxin. "The recruitment process for the …

Research on over need of booster dose against COVID-19: AIIMS doctor
3 years, 6 months ago

Research on over need of booster dose against COVID-19: AIIMS doctor

India TV News  

Research is taking place in India, US and several other countries to see if booster dose will be needed for maintaining longer efficacy of COVID-19 vaccines, a senior doctor has said. Everyone is looking towards the government, doctors and scientists if they are safe or they need a booster dose to make themselves safe. This is the important question and …

Discover Related